WuXi ATU Announces Licensing Agreement with Janssen for TESSA™ Technology

We are pleased to announce that WuXi ATU will license to Janssen its Tetracycline-Enabled Self-Silencing Adenovirus (TESSA™) technology, a high-performance system for adeno-associated viral vector (AAV) manufacture. Janssen will also have access to work on WuXi ATU’s proprietary clonal suspension HEK293 cell line.

TESSA™ technology produces higher quality AAV particles more efficiently. With a 10-fold higher yield and a significantly higher percentage of full AAV capsids, it greatly reduces overall AAV production costs compared to traditional plasmid-based AAV production systems.

As a Contract Testing, Development and Manufacturing Organization (CTDMO) with global operations, WuXi ATU will continue to enhance its capability and capacity to help customers develop and deliver life-changing cell and gene therapies faster for patients in need.

Read more here: https://bit.ly/3bJSYyw